GT200500383A - Sulfonamido-macrociclos y sus sales, una composicion farmaceutica que comprende estos compuestos, un metodo de preparacion y el uso de los mismos - Google Patents

Sulfonamido-macrociclos y sus sales, una composicion farmaceutica que comprende estos compuestos, un metodo de preparacion y el uso de los mismos

Info

Publication number
GT200500383A
GT200500383A GT200500383A GT200500383A GT200500383A GT 200500383 A GT200500383 A GT 200500383A GT 200500383 A GT200500383 A GT 200500383A GT 200500383 A GT200500383 A GT 200500383A GT 200500383 A GT200500383 A GT 200500383A
Authority
GT
Guatemala
Prior art keywords
compounds
macrociclos
sulfonamido
salts
preparation
Prior art date
Application number
GT200500383A
Other languages
English (en)
Inventor
Manfred Husemann
Wolfgang Schwede
Karl-Heinz Thierauch
Martina Schaefer
Ulrich Luecking
Andreas Huth
Hans Briem
Georg Kettschau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200500383A publication Critical patent/GT200500383A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL COMPUESTO DE FORMULA GENERAL I EN LA QUE R1,R2,R3, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS ACTUAN EN CONTRA DEL CRECIMIENTO VASCULAR DESREGULADO POR LO QUE SON DE UTILIDAD EN LA ANGIOGENESIS EN EL TEJIDO TUMORAL.
GT200500383A 2004-12-22 2005-12-21 Sulfonamido-macrociclos y sus sales, una composicion farmaceutica que comprende estos compuestos, un metodo de preparacion y el uso de los mismos GT200500383A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04090509A EP1674470A1 (en) 2004-12-22 2004-12-22 Sulfonamido-macrocycles as Tie2 inhibitors

Publications (1)

Publication Number Publication Date
GT200500383A true GT200500383A (es) 2006-08-03

Family

ID=34928853

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500383A GT200500383A (es) 2004-12-22 2005-12-21 Sulfonamido-macrociclos y sus sales, una composicion farmaceutica que comprende estos compuestos, un metodo de preparacion y el uso de los mismos

Country Status (15)

Country Link
EP (2) EP1674470A1 (es)
JP (1) JP2008524303A (es)
KR (1) KR20070099619A (es)
CN (1) CN101087798A (es)
AR (1) AR052175A1 (es)
AU (1) AU2005318361A1 (es)
BR (1) BRPI0519268A2 (es)
CA (1) CA2590742A1 (es)
GT (1) GT200500383A (es)
IL (1) IL182834A0 (es)
NO (1) NO20073818L (es)
PA (1) PA8658001A1 (es)
PE (1) PE20060881A1 (es)
TW (1) TW200635935A (es)
WO (1) WO2006066957A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1873159A1 (en) * 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Substituted sulphonamido-macrocycles as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1870416A1 (en) * 2006-06-21 2007-12-26 Bayer Schering Pharma Aktiengesellschaft Sulphonamido-macrocycles as tie2 inhibitors
EP2274288A2 (en) 2008-04-24 2011-01-19 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
WO2009158432A2 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
EP3356373B1 (en) 2015-09-29 2020-02-19 Bayer Pharma Aktiengesellschaft Novel macrocyclic sulfondiimine compounds
JP6888000B2 (ja) * 2015-10-08 2021-06-16 バイエル ファーマ アクチエンゲゼルシャフト 新規な修飾された大環状化合物
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
WO2018177889A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
ES2900199T3 (es) 2017-03-28 2022-03-16 Bayer Ag Novedosos compuestos macrocíclicos inhibidores de PTEFB
CN115677616A (zh) * 2021-11-03 2023-02-03 中国药科大学 大环磺酰胺类化合物及其制备方法和医药用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074515A1 (en) * 2002-03-01 2003-09-12 Smithkline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
DE10239042A1 (de) * 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
EP1674470A1 (en) 2006-06-28
PA8658001A1 (es) 2006-09-22
CA2590742A1 (en) 2006-06-29
IL182834A0 (en) 2007-08-19
CN101087798A (zh) 2007-12-12
WO2006066957A2 (en) 2006-06-29
PE20060881A1 (es) 2006-10-01
WO2006066957A3 (en) 2006-08-31
KR20070099619A (ko) 2007-10-09
BRPI0519268A2 (pt) 2009-01-06
NO20073818L (no) 2007-09-21
AR052175A1 (es) 2007-03-07
EP1844056A2 (en) 2007-10-17
AU2005318361A1 (en) 2006-06-29
TW200635935A (en) 2006-10-16
JP2008524303A (ja) 2008-07-10

Similar Documents

Publication Publication Date Title
GT200500383A (es) Sulfonamido-macrociclos y sus sales, una composicion farmaceutica que comprende estos compuestos, un metodo de preparacion y el uso de los mismos
UY29469A1 (es) Compuestos sulfoximino-macrocíclicos y sus sales, composiciones farmacéuticas que comprenden dichos compuestos, métodos de preparación y usos de los mismos.
GT200500242A (es) Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
DOP2016000250A (es) Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa
CU20100062A7 (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteínas quinasas b
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
GT200500325A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa
UY32455A (es) Derivados de aminotetralina, composiciones farmacéuticas que la contienen, y sus usos en terapia
ECSP088587A (es) Compuestos de piperidina 3,5-sustituida como inhibidores de renina
HN2002000067A (es) Inhibidores de la rho - quinasa.
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
GT200400092A (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
ECSP10010599A (es) Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)
ECSP12011880A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
CR20110059A (es) Compuestos organicos
DOP2013000142A (es) Derivados de biciclo[3,2,1]octilamida y sus usos.
CO6531452A2 (es) Piperidinas sustituidas que aumentan la actividad de p53 y sus usos
CO6321276A2 (es) Derivados de tiazol usados como inhibidores de pi3- cinasa
UY29343A1 (es) Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso.
ECSP088963A (es) Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmacéuticas que las comprenden
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
GT200500292A (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica
CR11859A (es) Composición y proceso-356
AR076263A1 (es) Composiciones y metodos para tratar cancer. uso.